The Role of Elastography in the Diagnosis of Thyroid Nodules
2 other identifiers
interventional
188
1 country
1
Brief Summary
The primary objective of this study is to evaluate the role of elastography (along with echographic and cytological data) as a diagnostic tool for thyroid cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2011
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 8, 2011
CompletedFirst Posted
Study publicly available on registry
February 9, 2011
CompletedStudy Start
First participant enrolled
November 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2014
CompletedMarch 27, 2015
March 1, 2015
2.8 years
February 8, 2011
March 26, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The difference between AUCs for the reference diagnostic method (cytology alone)and the new (cytology + elastography) diagnostic method.
Areas under the curves are estimated using the Wilcoxon-Mann-Chitney statistic. The gold standard is determined by anatomopathological examination of the excised tumor.
15 days
Study Arms (1)
The study population
EXPERIMENTALThe study population consists of patients for whom an echo-guided fine-needle aspiration was performed for one or more thyroid nodes, and for whom surgical node excision is required.
Interventions
A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
Eligibility Criteria
You may qualify if:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is available for six months of follow-up
- The patient is programmed for surgical excision of all nodules determined to be not benign according to cytological criteria
You may not qualify if:
- The patient is participating in another study
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient is pregnant
- The patient is breastfeeding
- The patient has a contraindication for a treatment used in this study
- The patient has a contraindication for surgical excision of his/her thyroid nodule
- The patient refused to be operated
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, Gard, 30029, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Véronique Taillard, MD
Centre Hospitalier Universitaire de Nîmes
- STUDY DIRECTOR
Haitham Sharara, MD
Centre Hospitalier Universitaire de Nîmes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 8, 2011
First Posted
February 9, 2011
Study Start
November 1, 2011
Primary Completion
August 1, 2014
Study Completion
August 1, 2014
Last Updated
March 27, 2015
Record last verified: 2015-03